These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 30670497)

  • 21. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
    Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
    Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
    Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
    Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
    J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
    Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
    Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
    Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
    J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
    Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
    PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
    Lin Z; Xiao S; Qi Y; Guo J; Lu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
    Lee J; Kim B; Jung HA; La Choi Y; Sun JM
    Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
    Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
    Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
    Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
    J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.
    Santagata S; Trotta AM; D'Alterio C; Napolitano M; Rea G; Di Napoli M; Portella L; Ieranò C; Guardascione G; Coppola E; Caux C; Dubois B; Boyle HJ; Carles J; Rossetti S; Azzaro R; Feroce F; Perdonà S; Fordellone M; Bello AM; Califano D; Chiodini P; Pignata S; Scala S
    Clin Cancer Res; 2024 Oct; 30(20):4755-4767. PubMed ID: 39167621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
    Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
    Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
    Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.